CPSE:GMABBiotechs
Genmab’s Valuation in Focus After Recent Pipeline Collaboration and Price Swings
If you are eyeing Genmab’s stock right now, you are certainly not alone. After a sharp 6.2% rally over the past month, the stock has given up some of those gains with a -9.2% slip in the last week. But don’t let short-term swings distract you from the surprising longer-term resilience here. Genmab is still up 26.6% since January and has gained 22.8% over the past year, even as the wider biotech sector has had its share of shake-ups.
What is driving all this movement? It has been a mix of...